Article
Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study.
Translational psychiatry - 6 Sept 2022
Islam Farhana, Marshe Victoria S, Magarbeh Leen, Frey Benicio N, Milev Roumen V, Soares Claudio N, Parikh Sagar V, Placenza Franca, Strother Stephen C, Hassel Stefanie, Taylor Valerie H, Leri Francesco, Blier Pierre, Uher Rudolf, Farzan Faranak, Lam Raymond W, Turecki Gustavo, Foster Jane A, Rotzinger Susan, Kennedy Sidney H, Müller Daniel J
Abstract excerpt
Cytochrome P450 drug-metabolizing enzymes may contribute to interindividual differences in antidepressant outcomes. We investigated the effects of CYP2C19 and CYP2D6 gene variants on response, tolerability, and serum concentrations. Patients (N = 178) were treated with escitalopram (ESC) from weeks 0-8 (Phase I), and at week 8, either continued ESC if they were responders or were augmented with aripiprazole (ARI)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.